Notice of Results

RNS Number : 2848U

IXICO plc

22 November 2019

 

 22 November 2019

IXICO plc

("IXICO" or the "Company")

Notice of Results

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, will announce its final results for the year ended 30 September 2019 on Wednesday, 4 December 2019.

Giulio Cerroni, CEO and Grant Nash, CFO, will host a breakfast briefing and call for analysts at 09:00 GMT on the day of the results.  Further details will be provided on request.

For further information please contact:

IXICO plc	[phone]
Giulio Cerroni, Chief Executive Officer
Cenkos Securities PLC (Nominated adviser and sole broker)	[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Optimum Strategic Communications	[phone]
Mary Clark / Supriya Mathur / Manel Mateus
[e-mail]

About IXICO

IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease. 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

More information is available on www.IXICO.com

 

END

 

 

NORBRBDBUSDBGCB